---
title: "CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293389069.md"
description: "A robust pipeline targets major endocrine diseases, with PALSONIFY showing strong launch metrics and clinical efficacy in acromegaly. Atumelnant and CRN09682 advance in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. $1.3B cash funds operations into 2030.Original document: Crinetics Pharmaceuticals, Inc. [CRNX] Slides Release — Jul. 21 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-21T21:25:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293389069.md)
  - [en](https://longbridge.com/en/news/293389069.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293389069.md)
generator: "portal-rs"
---

# CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030

A robust pipeline targets major endocrine diseases, with PALSONIFY showing strong launch metrics and clinical efficacy in acromegaly. Atumelnant and CRN09682 advance in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. $1.3B cash funds operations into 2030.

Original document: Crinetics Pharmaceuticals, Inc. \[CRNX\] Slides Release — Jul. 21 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)

## Related News & Research

- [Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference](https://longbridge.com/en/news/298804783.md)
- [Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis](https://longbridge.com/en/news/298806080.md)
- [IONS: Breakthrough approvals and robust launches drive growth, with a deep pipeline advancing in CNS and metabolic diseases](https://longbridge.com/en/news/299192045.md)
- [VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead](https://longbridge.com/en/news/298920359.md)
- [BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned](https://longbridge.com/en/news/299043586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**